The tweet was deleted by the author.
But we saved everything 🙂.
Michael Taylor, co-founder / portfolio manager at Agora Trading, expressed serious concerns about CAPR, calling the efficacy data presented by the company and the analysis by the FDA both conflicting and shocking.
Taylor pointed out that discrepancies exist in documents released today and questioned the reliability of the information provided.
Taylor has scrutinized market volatility across sectors in previous commentary. He recently examined whether an AI sector rally could drive a selloff in the XBI biotech ETF. Taylor also described unusual single-name volatility in a Kospi trading session, citing unique market conditions.